FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

11 letters match. Newest first.

  1. Curia New York, Inc.

    FDA warned Curia New York's Rensselaer, New York API plant that undocumented lab injections, shredded records and shared passwords violate CGMP.

    High risk
  2. Laboratorios Jaloma S.A. de C.V.

    FDA found Laboratorios Jaloma’s OTC drug lab records were inaccurate, microbial tests unvalidated, and electronic data missing or uncontrolled.

    High risk
  3. Tower Laboratories Ltd.

    FDA warned Tower Laboratories, an OTC drug maker in Montague, MI, for weak out-of-specification investigations and unproven test methods.

    High risk
  4. Unipack LLC

    FDA says Unipack LLC released suppositories without adequate out-of-specification investigations, complete lab records, and required USP testing.

    High risk
  5. Taizhou Kangping Medical Science and Technology Co., Ltd.

    FDA warns Taizhou Kangping about over-the-counter drugs labeled sterile that were not sterilized.

    High risk
  6. Chromatography Institute of America dba Compounder’s International Analytical Laboratory

    FDA warned Chromatography Institute of America, a Colorado contract drug testing lab, that sterility testing and quality controls violated current good manufacturing practice.

    High risk
  7. Taizhou Jingshang Cosmetics Technology Co., Ltd.

    FDA warns Taizhou Jingshang Cosmetics Technology over current good manufacturing practice failures in over-the-counter drugs, including missing identity tests for high-risk ingredients.

    High risk
  8. Indoco Remedies Limited

    FDA warned Indoco Remedies over manufacturing quality failures at its Goa plant, including unreliable microbial testing and aseptic processing deficiencies.

    High risk
  9. Nortec Quimica SA

    FDA warned Brazil's Nortec Quimica, an API maker, over deleted lab data and weak quality unit review of batches exported to the U.S.

    High risk
  10. Adamson Analytical Laboratories, Inc.

    FDA warned California contract drug-testing lab Adamson over inadequate computer controls and data integrity failures.

    High risk
  11. Lepu Medical Technology -Beijing- Co., Ltd.

    FDA warns Lepu Medical Technology Beijing that its unapproved COVID-19 test kits are adulterated and misbranded.

    High risk